title: Suppression of airway inflammation by theophylline in adult bronchial asthma.
abstract: BACKGROUND
  Chronic continuous airway inflammation caused by eosinophils has been noted to play critical roles in the pathophysiology of bronchial asthma, in addition to reversible obstruction and hypersensitivity of the respiratory tract. Therefore, suppression of chronic airway inflammation has become more important in asthma treatment. Although theophylline has been a conventionally used bronchodilator, it has been recently reported to have concurrent anti-inflammatory effects.
  
  
  OBJECTIVE
  Accordingly, we studied the effects of a slow-release theophylline preparation, Theolong, on airway inflammation.
  
  
  METHODS
  Administration of Theolong 400 mg/day to 24 patients with mild or moderate asthma and measuring eosinophil cationic protein (ECP), a marker of airway inflammation, and eosinophils in sputum and peripheral blood at 4 and 8 weeks.
  
  
  RESULTS
  As a result, sputum ECP, serum ECP and sputum eosinophil count (%) were significantly lowered after 4 and 8 weeks.
  
  
  CONCLUSIONS
  Thus, in the theophylline-administered group, slow-release theophylline, Theolong, was effective in treating asthma, with anti-inflammatory effects on inflammatory cells besides its bronchodilator action.
authors: Department of Internal Medicine, The Second Educational Hospital of Fujita Health University School of Medicine, Nagoya, Japan.
authors: T
authors: T
authors: Horiguchi
authors: S
authors: S
authors: Tachikawa
authors: J
authors: J
authors: Kasahara
authors: M
authors: M
authors: Doi
authors: M
authors: M
authors: Shiga
authors: J
authors: J
authors: Miyazaki
authors: Y
authors: Y
authors: Sasaki
authors: M
authors: M
authors: Hirose
authors: M
authors: M
authors: Imazu
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis*; D001991:Bronchitis / Q000209:etiology / Q000517:prevention & control; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D047091:Eosinophil Granule Proteins; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D018836:Inflammation Mediators / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012137:Respiratory System / Q000187:drug effects / Q000503:physiopathology; D012260:Ribonucleases; D013183:Sputum / Q000166:cytology; D018709:Statistics, Nonparametric; D013806:Theophylline / Q000008:administration & dosage*
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D013806:Theophylline; D012260:Ribonucleases